	US 11,896,584 B2
	Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
Gyanu Lamichhane, Towson, MD (US); and J. Thomas Ippoliti, St. Paul, MN (US)
Assigned to THE JOHNS HOPKINS UNIVERSTY, Baltimore, MD (US); and UNIVERSITY OF ST. THOMAS, St. Paul, MN (US)
Filed by The Johns Hopkins University, Baltimore, MD (US); and University of St. Thomas, St. Paul, MN (US)
Filed on Dec. 1, 2022, as Appl. No. 18/060,823.
Application 18/060,823 is a continuation of application No. 17/326,166, filed on May 20, 2021, granted, now 11,524,002.
Application 17/326,166 is a continuation of application No. 15/999,253, granted, now 11,040,025, issued on Jun. 22, 2021, previously published as PCT/US2017/018248, filed on Feb. 17, 2017.
Claims priority of provisional application 62/296,160, filed on Feb. 17, 2016.
Prior Publication US 2023/0099803 A1, Mar. 30, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4245 (2006.01)

CPC A61K 31/4245 (2013.01)

4 Claims

1. A method for treating or preventing a methicillin-sensitive and/or methicillin-resistant Staphylococcus aureus infection in a subject in need thereof, the method comprising administering to the subject an effective amount of (N—(((S)-3-(dibezo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.